Cargando…

Vascular Normalization: A New Window Opened for Cancer Therapies

Preclinical and clinical antiangiogenic approaches, with multiple side effects such as resistance, have not been proved to be very successful in treating tumor blood vessels which are important targets for tumor therapy. Meanwhile, restoring aberrant tumor blood vessels, known as tumor vascular norm...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ting, Xiao, Hongqi, Liu, Xiaoxia, Wang, Zhihui, Zhang, Qingbai, Wei, Nianjin, Guo, Xinggang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406857/
https://www.ncbi.nlm.nih.gov/pubmed/34476218
http://dx.doi.org/10.3389/fonc.2021.719836
_version_ 1783746566278873088
author Yang, Ting
Xiao, Hongqi
Liu, Xiaoxia
Wang, Zhihui
Zhang, Qingbai
Wei, Nianjin
Guo, Xinggang
author_facet Yang, Ting
Xiao, Hongqi
Liu, Xiaoxia
Wang, Zhihui
Zhang, Qingbai
Wei, Nianjin
Guo, Xinggang
author_sort Yang, Ting
collection PubMed
description Preclinical and clinical antiangiogenic approaches, with multiple side effects such as resistance, have not been proved to be very successful in treating tumor blood vessels which are important targets for tumor therapy. Meanwhile, restoring aberrant tumor blood vessels, known as tumor vascular normalization, has been shown not only capable of reducing tumor invasion and metastasis but also of enhancing the effectiveness of chemotherapy, radiation therapy, and immunotherapy. In addition to the introduction of such methods of promoting tumor vascular normalization such as maintaining the balance between proangiogenic and antiangiogenic factors and targeting endothelial cell metabolism, microRNAs, and the extracellular matrix, the latest molecular mechanisms and the potential connections between them were primarily explored. In particular, the immunotherapy-induced normalization of blood vessels further promotes infiltration of immune effector cells, which in turn improves immunotherapy, thus forming an enhanced loop. Thus, immunotherapy in combination with antiangiogenic agents is recommended. Finally, we introduce the imaging technologies and serum markers, which can be used to determine the window for tumor vascular normalization.
format Online
Article
Text
id pubmed-8406857
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84068572021-09-01 Vascular Normalization: A New Window Opened for Cancer Therapies Yang, Ting Xiao, Hongqi Liu, Xiaoxia Wang, Zhihui Zhang, Qingbai Wei, Nianjin Guo, Xinggang Front Oncol Oncology Preclinical and clinical antiangiogenic approaches, with multiple side effects such as resistance, have not been proved to be very successful in treating tumor blood vessels which are important targets for tumor therapy. Meanwhile, restoring aberrant tumor blood vessels, known as tumor vascular normalization, has been shown not only capable of reducing tumor invasion and metastasis but also of enhancing the effectiveness of chemotherapy, radiation therapy, and immunotherapy. In addition to the introduction of such methods of promoting tumor vascular normalization such as maintaining the balance between proangiogenic and antiangiogenic factors and targeting endothelial cell metabolism, microRNAs, and the extracellular matrix, the latest molecular mechanisms and the potential connections between them were primarily explored. In particular, the immunotherapy-induced normalization of blood vessels further promotes infiltration of immune effector cells, which in turn improves immunotherapy, thus forming an enhanced loop. Thus, immunotherapy in combination with antiangiogenic agents is recommended. Finally, we introduce the imaging technologies and serum markers, which can be used to determine the window for tumor vascular normalization. Frontiers Media S.A. 2021-08-12 /pmc/articles/PMC8406857/ /pubmed/34476218 http://dx.doi.org/10.3389/fonc.2021.719836 Text en Copyright © 2021 Yang, Xiao, Liu, Wang, Zhang, Wei and Guo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Ting
Xiao, Hongqi
Liu, Xiaoxia
Wang, Zhihui
Zhang, Qingbai
Wei, Nianjin
Guo, Xinggang
Vascular Normalization: A New Window Opened for Cancer Therapies
title Vascular Normalization: A New Window Opened for Cancer Therapies
title_full Vascular Normalization: A New Window Opened for Cancer Therapies
title_fullStr Vascular Normalization: A New Window Opened for Cancer Therapies
title_full_unstemmed Vascular Normalization: A New Window Opened for Cancer Therapies
title_short Vascular Normalization: A New Window Opened for Cancer Therapies
title_sort vascular normalization: a new window opened for cancer therapies
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406857/
https://www.ncbi.nlm.nih.gov/pubmed/34476218
http://dx.doi.org/10.3389/fonc.2021.719836
work_keys_str_mv AT yangting vascularnormalizationanewwindowopenedforcancertherapies
AT xiaohongqi vascularnormalizationanewwindowopenedforcancertherapies
AT liuxiaoxia vascularnormalizationanewwindowopenedforcancertherapies
AT wangzhihui vascularnormalizationanewwindowopenedforcancertherapies
AT zhangqingbai vascularnormalizationanewwindowopenedforcancertherapies
AT weinianjin vascularnormalizationanewwindowopenedforcancertherapies
AT guoxinggang vascularnormalizationanewwindowopenedforcancertherapies